首页> 美国卫生研究院文献>Diabetes Care >Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

【2h】

Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

机译：非诺贝特和噻唑烷二酮治疗2型糖尿病HDL-C的悖论性降低：ACCORD脂质试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVETo determine the occurrence of extremely low HDL cholesterol (HDL-C) among participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial and to examine the relationship of this finding with treatment with fenofibrate and thiazolidinedione (TZD).

机译：目的确定在控制糖尿病心血管风险的行动（ACCORD）脂质试验中参与者中极低的HDL胆固醇（HDL-C）的发生，并研究该发现与非诺贝特和噻唑烷二酮（TZD）治疗之间的关系。

著录项

期刊名称 Diabetes Care
作者
Peter E. Linz; Laura C. Lovato; Robert P. Byington; Patrick J. O’Connor; Lawrence A. Leiter; Daniel Weiss; Rex W. Force; John R. Crouse; Faramarz Ismail-Beigi; Debra L. Simmons; Vasilios Papademetriou; Henry N. Ginsberg; Marshall B. Elam;
展开▼
作者单位

展开▼
年(卷),期 2014(37),3
年度 2014
页码 686–693
总页数 8
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: The ACCORD lipid trial [J] . Linz,P.E., Lovato,L.C., Byington,R.P., Diabetes care . 2014,第3期

机译：非诺贝特和噻唑烷二酮类药物治疗2型糖尿病的HDL-C降低矛盾：ACCORD脂质试验
2. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin [J] . Michel Farnier, Qian Dong, Arvind Shah, Lipids in Health Disease . 2011,第1期

机译：单独用芬纤维或与ezetimibe或ezetimibe / ezetimibe组合的血脂血症患者矛盾患者矛盾患者矛盾患者的矛盾降低发生率低
3. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. [J] . Derosa G, Cicero AE, Bertone G, Clinical therapeutics . 2004,第10期

机译：氟伐他汀+非诺贝特联合治疗与氟伐他汀单药联合治疗高脂血症，2型糖尿病和冠心病的比较：一项为期12个月的随机，双盲，对照试验。
4. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator^* [C] . Roberto Visentin, Michele Schiavon, Clemens Giegerich, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2018

机译：长效胰岛素在糖尿病治疗中的作用：采用UVA / Padova 1型糖尿病模拟器的Silico临床试验^*
5. Feasibility Study of a Randomized Controlled Trial Protocol to Examine the Effectiveness of Auriculotherapy (AT) in Improving Sleep Condition and Glycaemic Control in Clients with Type 2 Diabetes. [D] . Kwan, Yee Mei. 2013

机译：一项随机对照试验方案的可行性研究，以检查耳穴疗法（AT）改善2型糖尿病患者睡眠状况和血糖控制的有效性。
6. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin [O] . Michel Farnier, Qian Dong, Arvind Shah, 2011

机译：单独使用非诺贝特或与依泽替米贝或依泽替米贝/辛伐他汀联合治疗的血脂异常患者HDL-C水平降低的矛盾率低
7. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin [O] . Michel Farnier, Qian Dong, Arvind Shah, 2012

机译：单独使用非诺贝特或与依泽替米贝或依泽替米贝/辛伐他汀联合治疗的血脂异常患者HDL-C水平降低的矛盾率低

Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

摘要

著录项

相似文献

相关主题

期刊订阅